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Purpose: During radiation therapy for pediatric brain tumors, the brainstem is a critical organ at risk, possibly with different radio-
sensitivity across its substructures. In proton therapy, treatment planning is currently performed using a constant relative biological
effectiveness (RBE) of 1.1 (RBE1.1), whereas preclinical studies point toward spatial variability of this factor. To shed light on this
biological uncertainty, we investigated the spatial agreement between isodose maps produced by different RBE models, with
emphasis on (smaller) substructures of the brainstem.
Methods and Materials: Proton plans were recalculated using Monte Carlo simulations in 3 anonymized pediatric patients with brain
tumors (a craniopharyngioma, a low-grade glioma, and a posterior fossa ependymoma) to obtain dose and linear energy transfer
distributions. Doses and volume metrics for the brainstem and its substructures were calculated using a constant RBE1.1, 4
phenomenological RBE models with varying (a/b)x parameters, and with a simpler linear energy transfer-dependent model. The
spatial agreement between the dose distributions of constant RBE1.1 versus the variable RBE models was compared using the Dice
similarity coefficient.
Results: The spatial agreement between the variable RBE dose distributions and RBE1.1 decreased with increasing isodose levels in all
patient cases. The patient with ependymoma showed the greatest variation in dose and dose volumes, where V50Gy(RBE) in the brainstem
increased from 32% (RBE1.1) to 35% to 49% depending on the applied model, corresponding to a spatial agreement (Dice similarity
coefficient) between 0.79 and 0.95. The remaining patients showed similar trends, however, with lower absolute values due to lower
brainstem doses.
Conclusions: All phenomenological RBE models fully enclosed the isodose volumes of the constant RBE1.1, and the volumes based on
variable RBE spatially agreed. The spatial agreement was dependent on the isodose level, where higher isodose levels showed larger
expansions and less agreement between the variable RBE models and RBE1.1.
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Pediatric patients with brain tumors are often referred
to proton therapy instead of photon-based radiation ther-
apy with the aim of reducing doses to normal tissues.
Whereas proton therapy has the potential to increase the
conformity of the physical dose deposition, there is
considerable uncertainty connected to its relative biolog-
ical effectiveness (RBE). In current treatment planning
practice, protons are assumed to be uniformly 10% more
effective than photons, expressed as a constant RBE of
1.1 (RBE1.1). However, the RBE is known to vary
depending on several factors, such as the linear energy
transfer (LET), physical dose per fraction, tissue frac-
tionation sensitivity (ie, [a/b]x ratio in the linear quadratic
model), and clinical endpoint.1,2
Brainstem injury after cranial radiation therapy is a rare
but serious side effect3,4 and is a particular concern for
patients with tumors located in the vicinity of the brain-
stem.5 During treatment planning, maintaining the brain-
stem dose below established tolerance levels has the
highest priority. Substructures of the brainstem may, in
addition, have different radio-sensitivities,6,7 and to
enable further risk mitigation, smaller structures could
benefit from being constrained by separate tolerance dose
levels. To detect and apply dose limitations to sub-
structures, accurate modeling of the RBE is a prerequisite.
The RBE depends on the plan configuration, and the
LET distribution in the brainstem can be substantially
different depending on tumor location and field configu-
ration.8 The brainstem is furthermore recognized to have a
low (a/b)x ratio, which has been associated with higher
RBE.9,10 Clinical evidence of variable RBE is starting to
emerge; a recent study of pediatric patients with medul-
loblastoma who experienced brainstem morbidity after
proton therapy reported slightly elevated LET values in
areas of symptomatic image changes.11 Indications of
variable RBE in proton therapy have also been observed
in pediatric patients with ependymoma12 and glioma.13,14
Whereas proton treatment plans are commonly evalu-
ated based on dose-volume histograms, there has so far
been no systematic investigation of the spatial agreement of
different RBE models, nor has there been any examination
of how variable RBE models would influence the brain-
stem and substructures in pediatric patients with brain tu-
mors. Considering that all clinical data from proton therapy
are based on an RBE of 1.1, an important step toward
including this biological uncertainty is to identify how the
isodose maps from different variable RBE models spatially
correlate to volumes from constant RBE. If variable RBE
models scale incoherently in regard to dose level, (a/b)x
ratios, and LET, it could lead to conflicting criteria during
treatment planning depending on the RBE model, in
addition to complicating the evaluation of dose-volume
constraints based on variable RBE in a clinical setting.The main objective of this study was therefore to
investigate how different variable RBE models influence
isodose volumes in the brainstem and substructures for
typical pediatric brain tumor entities, and in particular to
identify potential spatial shifts between the isodose vol-
umes using variable and constant RBE models.
Methods and Materials
Patient materials and treatment plans
The patient material included computed tomography
and magnetic resonance imaging scans with structure
delineations for 3 anonymized pediatric patients with
brain tumors, with craniopharyngioma, a low-grade gli-
oma, and a posterior fossa ependymoma (located in vi-
cinity of the brainstem) (Fig E1). The full brainstem,
brainstem surface (outer 3 mm), and brainstem core
(brainstem cropped by 3 mm), in addition to the clinical
target volumes (CTVs) and planning target volumes
(PTVs) from the clinical structure set, were delineated for
treatment planning. The PTV was defined using a 3-mm
margin for the CTV. For the purpose of this study,
fused computed tomographyemagnetic resonance imag-
ing scans were used to further delineate the 3 main sub-
structures of the brainstem: the midbrain, pons, and
medulla oblongata.
The intensity modulated proton therapy (IMPT) plans
for the patients used 3 fields (1 vertex and 2 lateral
oblique fields) and a dose of 54 Gy(RBE) over 30 frac-
tions to the PTVs. For the patient with ependymoma, an
additional 3-fraction boost for a total of 5.4 Gy(RBE) was
delivered to the center of the PTV using 2 lateral
opposing fields. The IMPT plans were multifield opti-
mized based on an RBE of 1.1 in the Eclipse (Varian
Medical Systems, Palo Alto, CA) treatment planning
system.
Monte Carlo simulations
The IMPT plans were recalculated using the FLUKA
Monte Carlo code15,16,17 and Flair18 to obtain biological
doses, dose-averaged LET (LETd) distributions, and LET
spectra (details found in reference 8). Each treatment field
was simulated with 50 million primary particles to obtain
statistical uncertainties below 0.5% in the target volume.
The physical dose was scored for all particles, whereas the
LET was scored for primary and secondary protons only.
The quantities were scored in the patient geometries
employing Hounsfield units to material density conver-
sions as described by Schneider et al19 and Parodi et al.20
The dose and LET were further converted to their water
equivalent quantities using density ratios, resulting in
dose-to-water and LET-in-water. The scoring was done
on a voxel-by-voxel basis using the same grid and voxel
Figure 1 50 Gy(RBE) isodose curves ([a/b]x Z 2.1 Gy) and
LETd distributions for the 3 patients. Delineated structures are
midbrain (green), pons (blue), and medulla oblongata (yellow).
The LETd in voxels receiving doses below 0.1 Gy(RBE) ac-
cording to the RBE1.1 dose is set transparent. Abbreviations:
CAR Z Carabe; LETd Z dose-averaged linear energy transfer;
LWD Z LET-weighted dose; MCN Z McNamara; RBE Z
relative biological effectiveness; ROR Z Rørvik; WED Z
Wedenberg. (A color version of this figure is available at https://
doi.org/10.1016/j.adro.2020.08.008.)
Advances in Radiation Oncology: JanuaryeFebruary 2021 Spatial agreement of proton therapy dose 3size (1.95  1.95  1.00 mm3) that were used during the
IMPT plan optimization.
RBE models
To evaluate variable RBE-weighted dose distributions
we used 4 phenomenological RBE models: the Weden-
berg (WED),21 McNamara (MCN),22 and Carabe-
Fernandez (CAR)23 models (based on a linear relation
between RBE and LET). In addition, we used a model
developed by Rørvik et al (ROR)24 based on a nonlinear
relationship between RBE and LET. These models were
selected because they are based on a high number of
experimental data points for low (a/b)x ratios and LET
values, while at the same time predicting different RBEs
based on the remaining model dependencies. Further de-
tails on the different models are described elsewhere.25
Well-established data on (a/b)x ratios for the brain and
brainstem are limited and the uncertainties are large. To
evaluate the effect of variation in these parameters, the
patients were simulated using 3 different ratios26 of 2.1,7
2.5,27 and 3.3 Gy28 for the entire brain, including the
brainstem and its substructures.
Owing to the (a/b)x ratio uncertainties, we also used
the LET-weighted dose (LWD),29 which represents RBE
variations exclusively depending on LETd, disregarding
biological aspects such as the (a/b)x ratio. The LWD was
initially designed for LETd optimization of proton plans
and was normalized with a factor such that the RBE in the
center of a spread-out Bragg peak (range, 10 cm; modu-
lation width, 5 cm) equals 1.1.2,29 We therefore scaled the
LWD such that the median RBE was equal to 1.1 in the
CTV of the patient.
Analysis
The 3-dimensional spatial agreement of the isodose
volumes from the RBE models was compared using the
Dice similarity coefficient (DSC),30 that is, with DSC Z
1 representing full overlap between isodose volumes and
DSC Z 0 representing no overlap (Fig E2). The DSCs
were calculated for biological isodose volumes in 5
Gy(RBE) steps within the brainstem and its substructures
for each model relative to the RBE1.1 isodose volumes.
By employing logical relations, we also investigated
whether isodose volumes from the variable RBE models
would fully encompass the RBE1.1 volumes or if, in
certain cases, the isodose volumes would be shifted and
only partially overlap.
Results
The biological isodose volumes from the 4 phenome-
nological RBE models were systematically larger than
when calculated using LWD and RBE1.1 for all patientsand structures, and thereby extended further into the
brainstem. RBE1.1 and LWD showed similar isodose
volumes; however, for regions with higher LETd the
distance between the isodose curves increased (Fig 1). In
all cases, the isodose volumes from the 4 phenomeno-
logical RBE models fully enclosed the RBE1.1, whereas
the LWD was shifted by a negligible amount relative to
RBE1.1 for a few isodose levels and structures. The largest
shift resulted in an RBE1.1 volume of only 0.05 cm
3 that
was not included in the LWD volume.
The V50Gy(RBE) of the brainstem and its substructures
was higher when calculated with the 4 phenomenological
RBE models than according to the LWD model and with
RBE1.1 (Fig 2). For the patient with ependymoma, the
V50Gy(RBE) increased from 32% with RBE1.1 to 35% with
LWD (DSC, 0.95), 46% with ROR (DSC, 0.83), 48%
with CAR (DSC, 0.81), 49% with MCN (DSC, 0.80), and
49% with WED (DSC, 0.79). The trends were similar for
A B C
D E F
Figure 2 V50Gy(RBE) metrics and corresponding Dice similarity coefficients within the brainstem and substructures for the 3 patients.
(a/b)x Z 2.1 Gy was used for the phenomenological RBE models. Abbreviations: CAR Z Carabe; DSC Z dice similarity coefficient;
LWD Z LET-weighted dose; MCN Z McNamara; RBE Z relative biological effectiveness; ROR Z Rørvik; WED Z Wedenberg.
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values.
The dose distributions found with the LWD model
showed better spatial agreement in the brainstem with the
RBE1.1 dose than the 4 phenomenological RBE models at
all dose levels (Fig 3). The LWD also had the least increase
in RBE with respect to LETd (Fig E3). The spatial agree-
ment between the RBE1.1 isodoses and the 4 phenomeno-
logical RBE models showed the same trends at all dose
levels, with marginally higher DSCs for the ROR model and
marginally lower DSCs for the WED model (Fig 3). Across
the models the DSCs were relatively high for lower isodose
levels but decreased rapidly for higher doses (Fig 3). The
dose level at which the decrease occurred was dependent on
the evaluated patient, but the trends seen in the entirebrainstem were also apparent for the midbrain and pons (Fig
E4).
The trends for the variation in the median doses were
similar for all patients, typically with WED, MCN, and
CAR calculating the highest doses, followed by ROR,
LWD, and RBE1.1, respectively. In the patient with epen-
dymoma, the medulla oblongata received the highest median
dose of 49.3 Gy(RBE) using RBE1.1, increasing up to 56.7
Gy(RBE) for the WED model. For the patient with cranio-
pharyngioma, the highest median dose was observed in the
midbrain (RBE1.1: 7.7 Gy[RBE] up to WED: 11.3 Gy
[RBE]). Similarly, the midbrain in the patient with glioma
also reported the highest median dose of 51.0 Gy(RBE)
from RBE1.1, increasing up to 57.5 Gy(RBE) for the MCN




Figure 3 Dice similarity coefficients relative to RBE1.1 for every 5 Gy(RBE) isodose step in the brainstem for the 3 patients. (a/b)x Z
2.1 Gy was used for the phenomenological RBE models. Abbreviations: CAR Z Carabe; DSC Z dice similarity coefficient; LWD Z
LET-weighted dose; MCN Z McNamara; RBE Z relative biological effectiveness; ROR Z Rørvik; WED Z Wedenberg.
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brainstem relative to RBE1.1 in all patients, up to 10.5
Gy(RBE). For the substructures, the same model showed the
largest increase in the pons of 12.4 Gy(RBE) for the patient
with glioma (Table E1).
By changing the (a/b)x ratios from 2.1 to 2.5 and
3.3 Gy, the CAR model showed the largest variations
in the V50Gy(RBE), declining by 1.5% to 7.5% depend-
ing on the patient, with the DSC consequently
increasing. The WED, MCN, and ROR models showed
smaller variations (Fig 5). Among the 3 patients, the
patient with craniopharyngioma showed the largest
variations in RBE depending on the (a/b)x ratios (Fig
6); this was also the patient with the highest LET
values (Fig E5) and the overall lowest doses in the
brainstem (Fig 4).Discussion
In this study, we investigated how biological isodoses
from published variable RBE models spatially correlated
in the brainstem and its substructures for typical pediatric
brain tumor entities, accounting also for variation in the
tissue-dependent model parameters. There were variations
in absolute dose levels depending on the RBE model as
well as in how the biological isodose curves coincided.
The phenomenological RBE models (dependent on [a/
b]x, LET, and physical fraction dose) resulted in the
highest biological dose and the least spatial agreement
with the RBE1.1 isodose volumes. Furthermore, the DSCs,
and thereby spatial agreement, were seen to rapidly
decrease for higher isodose levels while the DSCs
increased when applying higher (a/b)x ratios.
A B C
Figure 4 Median dose (D50%) in the brainstem and substructures for the 3 patients. (a/b)x Z 2.1 Gy was used for the phenome-
nological RBE models. The medulla oblongata for the patient with glioma is not shown due to doses of 0 Gy(RBE). Abbreviations:
CAR Z Carabe; LWD Z LET-weighted dose; MCN Z McNamara; RBE Z relative biological effectiveness; ROR Z Rørvik; WED
Z Wedenberg.
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which brainstem structure showed the highest and lowest
increase in biological dose when comparing variable RBE
models to RBE1.1. These differences can mainly be
attributed to the variations of the patient cases. When
applying the same (a/b)x ratio for the brainstem and the
substructures, the difference in biological dose from var-
iable RBE models relative to RBE1.1 dose will solely
depend on the LET and physical dose distribution within
the brainstem. An increase in biological dose depends on
the combined effect of elevated LET and physical dose.
Although the patients with craniopharyngioma and gli-
oma had high LETd values in the medulla oblongata (Fig
E5), the physical dose was so low that it resulted in a
modest to no increase in absolute biological dose.
It has previously been demonstrated that variable RBE
models typically estimate higher biological dose
compared with RBE1.1.
10,25,31-33 Depending on the tumor
site and location relative to organs at risk, as well as the
treatment regime, variable RBE models may violate
established dose constraints. Because dose calculation
using variable RBE models is not particularly common in
clinical settings, having elemental knowledge on how
these models behave in different treatment scenarios is
therefore important, in particular when the RBE1.1 dose is
near organ dose limits. In a recent clinical investigation by
Gentile et al,34 it was suggested to keep V55Gy(RBE) (for
RBE1.1) in the brainstem below 6% for pediatric patients
with posterior fossa tumors. In our results, we showed that
the spatial agreement between isodose volumes from thevariable RBE models and RBE1.1 was lower for
increasing isodose levels, with an increased rate of change
for doses typically above 30 to 50 Gy(RBE) depending on
the patient case (Fig 3 and Fig E4). When comparing the
RBE1.1 isodose to a variable RBE model estimating a
larger isodose volume, the absolute difference between
the RBE1.1 and variable RBE volumes will be more or
less constant for different dose levels (Fig E6). However,
the ratio between the volumes increases rapidly when the
RBE1.1 volume approaches zero, thus leading to a
decrease in the spatial agreement. As a consequence, this
effect is most crucial near high-dose constraints of smaller
structures.
Although the increase in variable RBE dose relative
to RBE1.1 dose was pronounced, the differences among
the variable RBE models were limited and likely within
the uncertainties of the models.9,35 Furthermore, a
limitation of the phenomenological RBE models is that
they are purely based on in vitro cell survival data, and
it is uncertain if this survival relationship can be
directly translated to in vivo endpoints.36 RBE models
in general are also based on different data sets,
complicating the task of discriminating between dif-
ferences in biological dose due to applied data sets or
differences in modeling approaches.25
Literature on (a/b)x ratios for the brainstem is limited,
and the few reported ratios are not particularly well
established. We calculated substantially different spatial
agreement between the biological models and RBE1.1
depending on the applied (a/b)x ratios, and thus the
A B C
D E F
Figure 5 V50Gy(RBE) and corresponding Dice similarity coefficients in the brainstem for the 3 patients using (a/b)x Z 2.1, 2.5, and 3.3
Gy. Abbreviations: CAR Z Carabe; DSC Z dice similarity coefficient; MCN Z McNamara; RBE Z relative biological effectiveness;
ROR Z Rørvik; WED Z Wedenberg.
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modeling. By including several values reported in the
literature, it may be possible to bound a plausible interval
of RBE values. It should furthermore be acknowledged
that (a/b)x ratios are highly endpoint specific and may
slightly differ across the various substructures. The ma-
jority of our presented results were calculated using (a/b)x
Z 2.1 Gy, a value frequently applied for the brainstem in
literature.9,11,37 This value originates from an examination
of normal tissue complication probability for the brain-
stem in patients treated with radiosurgery for acoustic
neuroma,7 and the (a/b)x ratios may therefore becorrelated to that particular treatment modality. The 2
remaining (a/b)x ratios we applied were 2.5 and 3.3 Gy.
The former was primarily intended for comparison of
dose-fractionation schedules,27 whereas the latter is from
a study where they converted the reported ratio from a
linear quadratic model equivalent (a/b)x ratio of approx-
imately 4.2 Gy38 to fit their model.28
In conclusion, for the 3 tumor entities we have
explored in this study, the biological isodose surfaces
derived when using the variable RBE models extended
further into the brainstem compared with the RBE1.1 dose.


























































Figure 6 RBE volume histograms comparing differences between (a/b)x Z 2.1, 2.5, and 3.3 Gy for the brainstem. For reference, the
median LETd and dose from RBE1.1 in the brainstem for each patient are shown in the boxes in the bottom left corner. Abbreviations:
CAR Z Carabe; LETd Z dose-averaged linear energy transfer; MCN ZMcNamara; RBEZ relative biological effectiveness; ROR Z
Rørvik; WED Z Wedenberg.
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umes in all cases, and the shapes of the isodose volumes
from the phenomenological RBE models agreed spatially.
The spatial agreement between the variable RBE models
and RBE1.1 was highly dependent on the evaluated
isodose level, where higher doses led to larger isodose
expansions and less agreement. In a clinical setting, the
RBE effect may therefore particularly affect constraints
regarding high doses and small volumes such as
V55Gy(RBE). It is furthermore important to keep in mind
that current dose constraints are based on RBEZ 1.1, and
therefore derived dose constraints obtained through vari-
able RBE models are crucial for future RBE optimization
paradigms.
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